Shaking Off Meeting Rust to Attend In-Person SOHO 2022
Just as we were getting used to attending conferences via virtual platforms, SOHO 2022 kicks off as an in-person meeting.
Related Articles
Triple Combination Shows Early Promise in Newly Diagnosed, Transplant-Ineligible MM
Early results from the MagnetisMM-6 trial reveal promising efficacy of elranatamab, daratumumab, and lenalidomide in treating newly diagnosed multiple myeloma.
Exploring a Triplet Approach to Kidney Cancer Treatment
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Anito-Cel Shows Durable Responses in Heavily Pretreated R/R Multiple Myeloma
New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and minimal residual disease negativity.
Dr Hamilton on Emi-Le: A Novel Payload ADC in Breast Cancer
Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.
Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC
During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and compared the use of…
George Shares Takeaways From IO Trials and AE Management in Pretreated RCC
During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.
BGB-16673 Shows Promise in Relapsed/Refractory CLL/SLL
New trial results reveal BGB-16673’s promising safety and efficacy in treating relapsed CLL/SLL, showing significant antitumor activity across diverse patient profiles.
Behind the C-144-01 Study of Lifileucel in Melanoma
Theresa Medina, MD, discusses treatment with lifileucel in patients with advanced melanoma and the background of the C-144-01 study.
Cervical Cancer: A Preventable Global Health Crisis for Women
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL
During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.